Hyperbaric oxygen therapy (HBOT) may reduce the risk of dying, the time to pain relief, and the chance of future heart attacks
in people with acute coronary syndrome. HBOT is thought to increase the supply of oxygen to the heart and may decrease the area of damage
and death in the heart muscle. More research is needed to confirm the efficacy of HBOT in conjunction with standard regimens
and to identify the types of patients who may benefit.
In 2004, and then in September 2014, the Cochrane Heart Group reviewed 6 randomized controlled trials with 665 participants.
The review authors conclude there is some evidence HBOT may reduce the risk of death, amount of heart damage, and duration of pain
for patients experiencing heart attack and severe angina. At the same time, they note limitations in the studies they evaluated
and conclude more substantial research is required before the benefits of HBOT for ACS patients are proven. Lacking that evidence,
HBOT cannot be recommended for routine treatment of heart attack or severe angina according to the authors.
[ Cochrane, 2015 ]
As of mid-2015 there are no registered studies investigating the treatment of acute coronary syndrome with hyperbaric oxygen therapy.
[ ClinicalTrials.gov ]
Without a large, well-controlled study underway the body of evidence for this use of hyperbaric oxygen will remain at promising, at best.